JONATHAN REITMAN: Open Payments
NPI 1922157320 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,525 in 55 payments from 13 companies in 2025. Trend: 2023 $1,692 · 2024 $1,976 · 2025 $1,525
Food & beverage: $1,525
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $378 |
| Indivior Inc. | 8 | $239 |
| ABBVIE INC. | 8 | $232 |
| ViiV Healthcare Company | 7 | $202 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Gilead Sciences, Inc. | 2 | $64 |
| EMD Serono, Inc. | 2 | $55 |
| Amgen Inc. | 2 | $44 |
| Merck Sharp & Dohme LLC | 1 | $27 |
Products named: CAPLYTA, SUBLOCADE, VRAYLAR, APRETUDE, TRINTELLIX, RELISTOR, UBRELVY, OTEZLA.
Industry payments across CA — which companies pay providers there.
